Montelukast vs. inhaled low-dose budesonide as monotherapy in the treatment of mild persistent asthma: A randomized double blind controlled trial

Journal of Tropical Pediatrics

Volumn 53, Issue 5, 2007, Pages 325-330

  Kumar, Vikram ^a   Ramesh, P ^a   Lodha, Rakesh ^a   Pandey, R M ^a   Kabra, S K ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Budesonide; Mild persistent asthma; Montelukast

Indexed keywords

BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; MONTELUKAST; PLACEBO; SALBUTAMOL; THEOPHYLLINE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MILD PERSISTENT ASTHMA; MONOTHERAPY; PARENT; PREDICTION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEDATION; SIDE EFFECT; SPIROMETRY; STATISTICAL SIGNIFICANCE; SYMPTOM; TREATMENT OUTCOME;

ACETATES; ADMINISTRATION, INHALATION; ADOLESCENT; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BUDESONIDE; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INDIA; MALE; QUINOLINES;

EID: 36248964696     PISSN: 01426338     EISSN: 14653664     Source Type: Journal    
DOI: 10.1093/tropej/fmm038     Document Type: Article

References (21)

1. National Asthma Education and Prevention Program. Expert Panel Report II: Guidelines for the Diagnosis and Management of Asthma: NHLBI Workshop Report. Bethesda, MD: National Heart, Lung, and Blood Institute, National Institutes of Health, 1995.
2. Ducharame FM, Davis GM. Randomized controlled trial of ipratropium bromide and frequent low doses of salbutamol in management of asthma. J Pediatrics 1998;133:475-85.
3. Gergen PJ, Weiss KB. Changing patterns of asthma hospitalization among children: 1979 to 1987. JAMA 1990;264:1688-92.
4. Capristo C, Rigotti E, Boner AL. Update on the use of montelukast in pediatric asthma. Allergy Asthma Proc 2006;27:312-8.
5. Noonan MJ, Chervinsky P, Brandon M, et al. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group. Eur Respir J 1998;11:1232-9.
6. Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: A multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 1998;158:1213-20.
7. Reiss TF, Altman LC, Chervinsky P, et al. Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 1996;98:528-34.
8. Altman LC, Munk Z, Seltzer J, et al. A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study Group. J allergy Clin Immunol 1998;102:50-6.
9. Busse W, Raphael GD, Galant S, et al. Fluticasone Proprionate Clinical Research Study Group. Low-dose fluticasone proprionate compared with montelukast for first-line treatment of persistent asthma: A randomized clinical trial. J Allergy Clin Immunol 2001;107:461-8.
10. Calhoun WJ, Nelson HS, Nathan RA, et al. Comparison of fluticasone propionate - salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting β2-agonists alone. Am J Respir Crit Care Med 2001;164:759-63.
11. Sorkness CA, Lemanske RF, Jr, Mauger DT, et al. For the Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: The pediatric asthma controller trial. J Allergy Clin Immunol 2007;119:64-72.
12. Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001;108:e48.
13. Muijsers RB, Noble S. Montelukast: A review of its therapeutic potential in asthma in children 2 to 14 years of age. Paediatr Drugs 2002;4:123-39.
14. Warner JO. The role of leukotriene receptor antagonists in the treatment of chronic asthma in childhood. Allergy 2001;56 (Suppl 66): 22-9.
15. Kanniess F, Richter K, Böhme S, et al. Montelukast versus fluticasone: Effects on lung function, airway responsiveness and inflammation in moderate asthma. Eur Respir J 2002;20:853-8.
16. Garcia Garcia ML, Wahn U, Gilles L, et al. Montelukast compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: The MOSAIC study. Pediatrics 2005;116:360-9.
17. Zeiger RS, Bird SR, Kaplan MS, et al. Short-term and long-term asthma control in patients with mild persistent asthma receiving montelukast or fluticasone: A randomized controlled trial. Am J Med 2005;118:649-57.
18. Ostrom NK, Decotiis BA, Lincourt WR, et al. Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma. J Pediatr 2005;147:213-20.
19. Becker A, Swern A, Tozzi CA, et al. Montelukast in asthmatic patients 6 years-14 years old with an FEV1 > 75%. Curr Med Res Opin 2004;201651-9.
20. Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6- to 14-year-old children: A randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA 1998;279:1181-6.
21. van Adelsberg J, Moy J, Wei LX, et al. Safety, tolerability, and exploratory efficacy of montelukast in 6 to 24 month-old patients with asthma. Curr Med Res Opin 2005;21:971-9.